

**Examiner-Initiated Interview Summary**

Application No.	Applicant(s)	
09/913,521	MATSUYAMA ET AL.	
Examiner	Art Unit	
J. Eric Angell	1635	

**All Participants:**(1) J. Eric Angell.**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_.

(2) Gene Rzucidlo.

(4) \_\_\_\_\_.

**Date of Interview:** 18 March 2004**Time:** \_\_\_\_\_**Type of Interview:**

- Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant  Applicant's representative)

Exhibit Shown or Demonstrated:  Yes  No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

*15 and withdrawn claims*

Prior art documents discussed:

**Part II.****SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

See Continuation Sheet

**Part III.**


- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner indicated to the Applicants' representative (Gene Rzucidlo) problems with claim 15, specifically with respect to claim 15 encompassing cancer preventing and hepatitis preventing agents. The Examiner proposed an amendment that would over come all rejections and make claim 15 allowable. Applicants' representative agreed to the amendment and approved the instant Examiner's amendment which replaced claim 15 and cancelled the withdrawn claims..



DAVE T. NGUYEN  
PRIMARY EXAMINER